Vanda Pharmaceuticals Inc (VNDA)
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
📈 **POSITIVE** • Medium confidence analysis (74%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business